28 July 2018 | Statements

With targeted investment, hepatitis C can be beaten

Vials sit on a bench top being tested for HIV and Hepatitis C in the laboratory at community health centre Richard Toll, Thiabakh, Senegal in 2015 (Image: Sam Phelps/The Global Fund)

Hepatitis C (HCV) is a vastly under-diagnosed liver disease that kills 400,000 people a year, and is especially dangerous to people living with HIV. But today, on World Hepatitis Day, it’s essential to stress that HCV it is readily curable, and with innovative diagnostics and drugs, together with smart financing strategies, we can reach the global goal of eliminating HCV as a health threat by 2030. 

Unitaid is at the forefront of global efforts to eradicate this insidious and deadly disease. We have invested US $60 million in a set of complementary investments that draw on the strengths of our implementing partners, experts who are well-positioned to bring down the barriers to HCV diagnosis and treatment. 

Our HCV grant projects are focused on providing simplified and more affordable treatment in lower-income countries, more affordable medicines, increased awareness and demand-generation, and better point-of-care, rapid diagnostics. 

An estimated 71 million people worldwide suffer from chronic HCV infection, but only 20 percent know they are infected, and only 4 percent are treated. With the better drugs now available, 95 percent of those HCV infections can be cured in only 12 weeks. With greater awareness, attention and investment, a cure can be brought to those who need it.


View All News

Featured News

06 May 2021

Unitaid statement on US support for IP waiver for COVID-19 vaccines

Read More

28 April 2021

Unitaid and Wellcome statement regarding MSD’s global access plan for molnupiravir, a potential treatment for COVID-19 

Read More

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.